Combination of Serum Biomarkers to Differentiate Malignant From Benign Ovarian Tumours

In: Journal of Obstetrics and Gynaecology Canada · 2012 · vol. 34(6) , pp. 567–574 · doi:10.1016/s1701-2163(16)35273-2 · W11096098
article OA: closed CC0
View on OpenAlex View at publisher
AI-generated summary by claude@2026-07, 2026-07-20

This pilot study found that a regression model combining RMI-II scores with six serum biomarkers (CA 125, HE 4, IL-18, leptin, MIF, and FGF-2) differentiated malignant from benign ovarian tumours.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo investigate biomarkers and clinical parameters to distinguish ovarian cancers from benign ovarian tumours.MethodsSerum biomarkers (CA 125, human epididymis protein 4 [HE 4], interleukin-18 [IL-18], leptin, macrophage migration inhibitory factor [MIF], fibroblast growth factor 2 [FGF-2], insulin-like growth factor, osteopontin, prolactin) and the risk of malignancy indexes I and II (RMI-I and RMI-II) scores were obtained prior to surgery in 52 patients with ovarian tumours (37 malignant and 15 benign). ROC curves were built for each individual marker, for logistic regression models using all markers, and for models combining both biomarkers and RMI scores.ResultsThe model with nine biomarkers performed well (specificity 93%, sensitivity 84%) and was more reliable than the RMI-I or RMI-II alone. A regression model combining RMI-II and six of the biomarkers (CA 125, HE  4, IL-18, leptin, MIF, and FGF-2) allowed differentiation between the cancer and non-cancer cases in this pilot study.ConclusionThe regression models using biomarkers combined with clinical scoring systems warrant further investigation to improve triage of patients with ovarian tumours to enhance utilization of resources and optimize patient care.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (22)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK